Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Niki Karachaliou, MD"'
Autor:
Kaiwen Wang, PharmD, Robyn Du, BS, Sinchita Roy-Chowdhuri, MD, Ziping T. Li, MD, Lingzhi Hong, MD, Natalie Vokes, MD, Yasir Y. Elamin, MD, Celyne Bueno Hume, MD, Ferdinandos Skoulidis, MD, PhD, Carl M. Gay, MD, PhD, George Blumenschein, MD, Frank V. Fossella, MD, Anne Tsao, MD, Jianjun Zhang, MD, PhD, Niki Karachaliou, MD, Aurora O’Brate, PhD, Claudia-Nanette Gann, MD, Jeff Lewis, MS, Waree Rinsurongkawong, PhD, J. Jack Lee, PhD, MS, DDS, Don Lynn Gibbons, MD, PhD, Ara A. Vaporciyan, MD, John V. Heymach, MD, PhD, Mehmet Altan, MD, Xiuning Le, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100533- (2023)
Introduction: MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefi
Externí odkaz:
https://doaj.org/article/abe6440483814bd08d4c9b73ab459684
Autor:
Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz:
https://doaj.org/article/08a2152e29af4e089606394482732718
Autor:
Masaoki Ito, MD, Jordi Codony-Servat, PhD, Ana Giménez-Capitán, BSc, Mireia Serra-Mitjans, MD, Francisco Pérez-Ochoa, MD, David Llige, BSc, Imane Chaib, PhD, Ramón Rami-Porta, MD, Carme Obiols, MD, Sergi Call, MD, Manuela Iglesias, MD, José Belda-Sanchis, MD, Xavier Tarroch-Sarasa, MD, Niki Karachaliou, MD, Miguel Angel Molina-Vila, PhD, Morihito Okada, MD, Rafael Rosell, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100084- (2020)
Introduction: EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be p
Externí odkaz:
https://doaj.org/article/ba1595860e4f4a8a8b44fa1c6caeb13a